Myrbetriq Generic Name & Formulations
Mirabegron 25mg, 50mg; ext-rel tabs.
Beta-3 adrenergic agonist.
Tabs—30, 90; Granules—1
Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency, as monotherapy or in combination with solifenacin. Neurogenic detrusor overactivity (NDO) in pediatric patients aged ≥3yrs and weighing ≥35kg.
Myrbetriq Dosage and Administration
Swallow tabs whole with water. Initially 25mg once daily; may increase to max 50mg once daily after 4–8 weeks if needed. Severe renal impairment or moderate hepatic impairment: max 25mg once daily. ESRD, requiring dialysis, or severe hepatic impairment: not recommended.
<3yrs: not established. Swallow tabs whole with water. Take with food. ≥3yrs (≥35kg): Initially 25mg once daily; may increase to max 50mg once daily after 4–8 weeks if needed. Severe renal impairment or moderate hepatic impairment: max 25mg once daily. ESRD, requiring dialysis, or severe hepatic impairment: not recommended.
Myrbetriq Boxed Warnings
Do not substitute tabs and granules on a mg-per-mg basis. Severe uncontrolled hypertension: not recommended. Monitor blood pressure periodically. Significant bladder outlet obstruction, patients taking antimuscarinic drugs for OAB: risk of urinary retention. Discontinue and treat if angioedema of the tongue, hypopharynx, or larynx occurs. Pregnancy. Nursing mothers.
May potentiate CYP2D6 substrates (eg, metoprolol, desipramine); adjust dose and monitor esp. with narrow therapeutic index drugs (eg, thioridazine, flecainide, propafenone). Concomitant digoxin: use lowest digoxin dose initially (monitor and titrate).
Myrbetriq Adverse Reactions
Adults: hypertension, nasopharyngitis, UTI, headache; also with solifenacin: dry mouth, constipation, tachycardia. Children: UTI, nasopharyngitis, constipation, headache.
Myrbetriq Clinical Trials
Myrbetriq Patient Counseling